Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years
Next Competitor Likely Years Behind
Neurocrine will launch Crenessity for adults and children with classic congenital adrenal hyperplasia in less than a week, with pricing available then, adding its second commercial product.
